| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2002;74:865-869
© 2002 The Society of Thoracic Surgeons
a Department of Thoracic and Vascular Surgery, Fachkrankenhaus Coswig (Centre for Pneumology and Thoracic Surgery), Coswig/Dresden, Germany
b Department of Informatics, University Carl Gustav Carus, Dresden, Germany
c Division of Cardiothoracic Surgery, University of Texas Medical Branch, Galveston, Texas, USA
Accepted for publication May 19, 2002.
* Address reprint requests to Dr Zwischenberger, Division of Cardiothoracic Surgery, 301 University Blvd, University of Texas Medical Branch, Galveston, TX 77555-0528, USA
e-mail: jzwische{at}utmb.edu
Background. A new 1318-nm Nd:YAG laser has been developed to utilize the second wavelength (1318 nm; 40 watt) to more precisely cut, coagulate, and seal lung tissue adjacent to pulmonary nodules. This laser allows a precise intraparenchymal nodulectomy with a 5-mm rim of tissue destruction and subsequent lung parenchymal reapproximation to avoid lobar distortion. Resection of multiple, bilateral, and recurrent tumors in the lung is facilitated by this laser technique.
Methods. In 100 consecutive patients (53 men, mean age 60 years; 47 women, mean age 61 years) with various primaries (most commonly renal and colorectal), 155 laser resections were performed via anterolateral thoracotomy (staged 3 to 4 weeks, if bilateral) using a new 1318-nm Nd:YAG laser. All palpable and visible masses were removed with 2 to 3-mm visible tumor margins (plus a 5-mm rim of residual lung necrosis secondary to laser energy dispersal) if the tumor or residual lung ratio was judged favorable. No stapling devices or bioadhesives were used.
Results. Six hundred thirty-two metastases (6.3 per patient, range 1 to 124) were resected. Despite 41% centrally located metastases, tumor resections were possible in 95% of patients with only a 5% lobectomy rate. Of the 100 patients, 67 were considered "curative" with complete metastasectomy by inspection and palpation, and 23 were judged incomplete from too extensive tumor or residual lung, miliary lung spread, or pleural studding. There were no associated mortalities and two complications, including bleeding (1) and a prolonged airleak (1), both treated conservatively. Follow-up was complete in all patients for a median of 26.5 months with clinic visits and chest computed tomographic scan every 3 to 6 months. Nine recurrences were detected and underwent reoperation. Overall survival in the completely resected "curative" group was 85% at 1 year, 71% at 2 years, 69% at 3 years, 57% at 4 years, and 32% at 5 years; in the completely resected "palliative" group, they were 70% at 1 year, 36% at 2 years, 12% at 3 years, and 0 at 4 years; in the incomplete group, they were 56% at 1 year, 30% at 2 years, and 0 at 3 years.
Conclusions. The new 1318-nm Nd:YAG laser is parenchyma-sparing, improves complete resection rates, and potentially improves survival with fewer required lobectomies.
This article has been cited by other articles:
|
|
 |
|
  A. Rolle, A. Pereszlenyi, R. Koch, M. Richard, and B. Baier Is surgery for multiple lung metastases reasonable? A total of 328 consecutive patients with multiple-laser metastasectomies with a new 1318-nm Nd:YAG laser J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1236 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rolle and A. Pereszlenyi Laser resection of lung metastasis MMCTS, June 28, 2005; 2005(0628): 570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Jungraithmayr, J. Hasse, M. Olschewski, and E. Stoelben Indications and results of completion pneumonectomy Eur. J. Cardiothorac. Surg., July 1, 2004; 26(1): 189 - 196. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
